NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

BCAX

Bicara Therapeutics Inc

Apr 29 • 04:00PM ET

14.88

Dollar change +0.07
Percentage change 0.47	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IWO SCHA VTWO IWN FESM ONEQ TMSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	43.23%	Shs Outstand	54.44M	Perf Week	7.67%
Market Cap	811.31M	Forward P/E	-	EPS next Y	-2.27	Insider Trans	-0.33%	Shs Float	30.95M	Perf Month	11.04%
Income	-	PEG	-	EPS next Q	-0.41	Inst Own	55.47%	Short Float	17.42%	Perf Quarter	24.21%
Sales	-	P/S	-	EPS this Y	56.70%	Inst Trans	43.58%	Short Ratio	10.92	Perf Half Y	-34.19%
Book/sh	9.04	P/B	1.65	EPS next Y	-29.36%	ROA	-	Short Interest	5.39M	Perf Year	-
Cash/sh	8.98	P/C	1.66	EPS next 5Y	13.09%	ROE	-	52W Range	8.91 - 28.09	Perf YTD	-14.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-47.03%	Beta	-
Dividend TTM	-	Quick Ratio	27.93	Sales past 5Y	0.00%	Gross Margin	-	52W Low	67.00%	ATR (14)	1.45
Dividend Ex-Date	-	Current Ratio	27.93	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	61.64	Volatility	10.93% 13.11%
Employees	55	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.57	Target Price	33.20
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.94	Prev Close	14.81
Sales Surprise	-	EPS Surprise	-18.47%	Sales Q/Q	-	Earnings	Mar 27 BMO	Avg Volume	493.48K	Price	14.88
SMA20	20.43%	SMA50	14.42%	SMA200	-13.44%	Trades		Volume	465,331	Change	0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Initiated	Wells Fargo	Underweight	$8
Feb-06-25	Initiated	Wedbush	Outperform	$31
Dec-06-24	Initiated	H.C. Wainwright	Buy	$42
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$48
Oct-08-24	Initiated	TD Cowen	Buy
Oct-08-24	Initiated	Stifel	Buy	$47
Oct-08-24	Initiated	Morgan Stanley	Overweight	$35
Oct-08-24	Initiated	Cantor Fitzgerald	Overweight

Apr-28-25 04:01PM	Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-23-25 10:00AM	Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.23%
Apr-19-25 06:22AM	Bicara: Innovative Precision Tumor Targeting (Seeking Alpha)
Mar-27-25 07:30AM	Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-25 04:45PM	Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 (GlobeNewswire) -5.58%
04:01PM	Loading…
Feb-24-25 04:01PM	Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-11-25 04:01PM	Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jan-27-25 08:00AM	Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-08-25 10:16AM	Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia (Clinical Trials Arena)
Nov-12-24 07:30AM	Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.30%
Nov-11-24 04:01PM	Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Oct-08-24 10:44AM	MBX Biosciences earns Buy rating at three investment firms (Investing.com) -7.77%
Sep-23-24 07:05PM	RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares (GuruFocus.com)
Sep-19-24 01:13AM	TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
03:01PM	Loading…
Sep-18-24 03:01PM	FMR LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-17-24 09:13AM	Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity (Pharmaceutical Technology) +6.53%
Sep-16-24 04:01PM	Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.54%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 09:15PM	Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
07:02PM	Three biotechs raise $700M in rare burst of IPO activity (BioPharma Dive)

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Meisner Lara	Chief Legal Officer	Mar 14 '25	Option Exercise	5.45	79,146	431,346	79,145	Mar 18 06:35 PM
Meisner Lara	Chief Legal Officer	Mar 14 '25	Sale	12.90	79,146	1,021,211	0	Mar 18 06:35 PM
LARA S. MEISNER	Officer	Mar 14 '25	Proposed Sale	13.35	79,146	1,056,599		Mar 14 04:21 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 16 '24	Buy	18.00	1,833,000	32,994,000	4,303,418	Sep 18 06:02 PM
Flynn James E	Possible Members of 10% Group	Sep 17 '24	Buy	18.00	70,000	1,260,000	897,587	Sep 17 06:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCAX

Bicara Therapeutics Inc

Upgrade your FINVIZ experience